My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Merck & Co (NY:MRK)

100.69 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Dec 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9

...

98 99 Next >

Evaxion Stock Jumps A Whopping 43% Pre-Market – Here’s What Happened ↗

September 25, 2025

Via Stocktwits

Merck & Co. Inc. (NYSE:MRK): A Prime Candidate for a Dependable Dividend Portfolio ↗

September 25, 2025

Merck & Co. (MRK) offers a solid 3.97% dividend yield with a strong history of growth. Its reliable payout is backed by excellent profitability and a healthy balance sheet, making it a top choice for...

Via Chartmill

United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO ↗

September 24, 2025

Eli Lilly CEO Dave Ricks criticizes UK drug pricing and rebate rules as pharma giants scale back investments, warning of fewer new medicines.

Via Benzinga

The Smartest Dividend Stock to Buy With $1,000 Right Now ↗

September 24, 2025

Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.

Via The Motley Fool

Topics Intellectual Property

Should You Forget Pfizer and Buy These Unstoppable Stocks Instead? ↗

September 24, 2025

Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives.

Via The Motley Fool

Topics Intellectual Property

Price Over Earnings Overview: Merck & Co ↗

September 22, 2025

Via Benzinga

Merck Says EMA Committee Adopted Two Positive Opinions For Expanding Use Of Cancer Drug Keytruda ↗

September 19, 2025

Via Stocktwits

SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks? ↗

September 11, 2025

Via Stocktwits

3 Dividend Stocks Perfect for Millennial Investors ↗

September 24, 2025

All three of these names are not only built to last, they're being rebuilt to thrive for at least a few more decades.

Via The Motley Fool

Topics Economy Intellectual Property Retirement

The Magnificent 7 Boom Just Triggered A Dot-Com Era Warning ↗

September 23, 2025

The Magnificent Seven tech giants are now worth $21 trillion—8x more than top health care stocks, echoing dot-com bubble extremes.

Via Benzinga

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel' ↗

September 22, 2025

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current...

Via Benzinga

Topics Government

Merck Reportedly Scraps Research Centre In UK: Retail Sees Stock Rallying To $97.50 ↗

September 10, 2025

Via Stocktwits

Inflation's Lingering Shadow: Long-Term Expectations Rise Amidst Fed Rate Cuts

September 22, 2025

The financial markets are currently navigating a perplexing economic landscape where long-term inflation expectations are on the rise, even as the Federal Reserve initiates interest rate cuts. In...

Via MarketMinute

Topics Bonds ETFs Economy

FDA Clears Merck's One-Minute Cancer Shot ↗

September 22, 2025

FDA approves Merck's Keytruda Qlex injection for adults with solid tumors. Merck expects it to be available in the U.S. in September.

Via Benzinga

Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might

September 22, 2025

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Merck Snags A Key Approval Before Its Cash Cow Goes Off A Patent Cliff ↗

September 22, 2025

But that doesn't mean Keytruda is safe from the looming patent cliff.

Via Investor's Business Daily

Topics Intellectual Property

3 Dirt-Cheap Stocks to Buy Right Now ↗

September 22, 2025

These stocks share several common denominators, including attractive valuations.

Via The Motley Fool

Topics Intellectual Property

What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill ↗

September 20, 2025

A high yield is only one part of the story when it comes to picking dividend stocks.

Via The Motley Fool

Topics Intellectual Property

Merck Scores Positive Feedback From EU Agency Regarding Blockbuster Cancer Drug ↗

September 19, 2025

Merck received positive Keytruda notes from CHMP regarding its breakthrough cancer treatment with final decisions expected in late 2025.

Via Benzinga

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Via MarketMinute

Decoding Merck & Co's Options Activity: What's the Big Picture? ↗

September 19, 2025

Via Benzinga

Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?' ↗

September 18, 2025

Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps,...

Via Benzinga

Robert Kennedy Jr. Packs CDC Panel With Vaccine Skeptics Ahead of Key Vote On COVID-19 Shots ↗

September 15, 2025

Health and Human Services Secretary Robert F. Kennedy Jr. has added five new members to the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices, just days...

Via Benzinga

The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health

September 15, 2025

The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor...

Via MarketMinute

Merck & Co. Inc. (NYSE:MRK): A Prime Value Stock with Strong Profitability and Sound Finances ↗

September 15, 2025

Discover Merck & Co. (MRK), a top value stock with strong profitability, sound financial health, and an attractive valuation. A prime pick for value investors.

Via Chartmill

2 Healthcare Dividend Stocks to Buy and Hold ↗

September 14, 2025

These drugmakers have competitive yields and have increased their dividends at a good clip.

Via The Motley Fool

Topics Intellectual Property

Merck & Co. Inc. (NYSE:MRK) Excels in Caviar Cruise Quality Stock Screen ↗

September 13, 2025

Discover Merck & Co. (MRK), a top-tier stock excelling in profitability, high ROIC, strong cash flow, and a robust balance sheet for long-term quality investing.

Via Chartmill

Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs ↗

September 12, 2025

Pharmaceutical companies are pulling investment from the UK as NHS drug spending falls and pricing disputes worsen.

Via Benzinga

Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data ↗

September 11, 2025

Merck's Capvaxive vaccine showed strong immune responses and a comparable safety profile to PPSV23 in high-risk children during the Phase 3 STRIDE-13 trial.

Via Benzinga

Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch ↗

September 08, 2025

Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

98 99 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.